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because of tumor hypoxia there is a major opportunity to 
improve SABR by the use of hypoxic cell radiosensitizers. 
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The technological developments in radiotherapy have had a 
considerable impact on the way stereotactic radiotherapy is 
delivered. Increased confidence, provided for example, by 
the wide availability of image guidance, has permitted more 
and more institutions to offer SABR as a treatment option. 
However, some characteristics of SABR plans such as 
heterogeneous dose prescription, can make the comparison 
between different institutions and different technological 
approaches very challenging. In this session, we will review 
the impact of image guidance strategies, dose calculation 
algorithms, and normalization guidelines on the planned dose 
distribution. We will also discuss how these technological 
aspects should influence how we look at clinical trials of the 
past, and what should be taken into account when designing 
new multi-centre trials. 
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Purpose or Objective: SBRT is highly effective in providing 
local control in selected patients with hepatic malignancies. 
However, various dosing and fractionation schemes with a 
wide range of toxicity end-points have been reported in the 
literature. The objective of this work was to review the 
normal tissue dose-volume effects for liver SBRT and derive 
normal tissue complication probability models. 
 
Material and Methods: A literature review by the AAPM 
Working Group on SBRT was performed. Twelve studies that 
contained both dose/volume and toxicity data from 541 
patients with hepatocellular carcinoma, intrahepatic 
cholangiocarcinoma, and/or liver metastases were identified 
and analyzed. Patients received a median total dose of 40 Gy 
(range 18-60 Gy) in 1-6 fractions. The 3 end-points that were 
chosen for pooled dose-response relationships analysis were 
grade 3+ (G3+) liver enzyme elevation as a function of mean 
liver dose (MLD), G2+ GI toxicity as a function of prescription 
(RX) or PTV dose, and G3+ GI toxicities as a function of 
RX/PTV dose. The RX/PTV doses were chosen because doses 
to specific OARs were not available in many instances. Dose-
response modeling was performed using a probit model with 
maximum likelihood (ML) parameter fitting. The model used 
the average reported toxicity rates and corresponding dose 
metrics reported in each included study. The average toxicity 
rate was then binned into binary outcomes to facilitate ML 
parameter fitting. Confidence intervals for dose-response 
curves were calculated using bootstrap method using random 
sampling with replacement.  
 
Results: Increased MLD was positively correlated with G3+ 
enzyme toxicity; however, the probit model fitting did not 
produce a statistically significant dose-response fit. Possible 
explanations are the sparsity of data, low incidence of 
complications, variations in baseline liver function and 
cancer type, and lack of standardization of definitions used 
for liver enzyme abnormalities. The analysis relating G2+ GI 
toxicity to RX/PTV dose showed a statistically significant 
probit model fit. Model fitting parameters were D50 of 47.7 
Gy (95% CI 43.0 - 68.8 Gy) and γ50 of 0.79 (95% CI 0.34 - 
1.25). The plot relating G3+ GI toxicity to RX/PTV dose 
demonstrated a dose response with a statistically significant 
probit model fit. Model fitting parameters were D50 of 90.2 
Gy (95% CI 67.2 - 516.4 Gy) and γ50 of 1.17 (95% CI 0.68 - 
1.69). The large D50 value of 90.2 Gy can be attributed to 
the low rates of G3+ GI toxicity. 
 
Conclusion: Our analysis shows a mean RX/PTV dose of 50 Gy 
in 3 to 6 fractions has resulted in G3+ GI toxicity risk of < 
10%. The QUANTEC liver report recommends MLD limits of 13 
Gy in 3 fractions and 18 Gy in 6 fractions for primary disease 
and 15 Gy in 3 fractions and 20 Gy in 6 fractions for 
metastases. Our analysis shows that the QUANTEC 
recommended MLD limits would likely result in acceptable 
G3+ liver enzyme toxicity risks of < 20%. 
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The group of Hans Clevers at the Hubrecht Institute 
discovered a unique marker (LGR5) for epithelial stem cells 
of the intestine (Barker et al., Nature 2007). Since then, 
LGR5 has been shown to be a marker of adult stem cells of 
multiple other tissues such as liver, pancreas, breast, and 
lung (eg: Huch et al., Nature 2013; Boj et al., Cell 2014; 
Karthaus et al., Cell 2014). With the identification of these 
stem cells and the tools to isolate them, we were able to 
develop a culture system that allowed for the virtually 
unlimited, genetically and phenotypically stable expansion of 
the cells from several animal models including human (Sato 
et al., Nature 2009, 2011; Gastroenterology 2011; Gao et al., 
Cell 2014; Boj et al., Cell 2015; Huch et al., Cell 2015; van de 
Wetering et al., in press Cell). The organoids faithfully 
represent the in vivo cells also after prolonged expansion in 
vitro. Hubrecht Organoid Technology (HUB), an entity 
founded to implement the organoid technology of the Clevers 
group, in collaboration with the Hubrecht institute, has 
generated a large collection of patient organoids from a 
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variety of organs and diseases. The intestinal organoids have 
been shown to be a very power tool for the study of Cancer, 
Cystic Fibrosis and Inflammatory Bowel Disease (Dekkers, Nat 
Med 2013; van de Wetering, Cell in press). The models 
represent previously unavailable in vitro models and patient 
specific samples for drug development, patient stratification 
and diagnostics. In addition, we recently showed the 
organoids are amendable to genetic corrections by novel and 
conventional biochemical techniques such as Crispr/Cas9 
(Drost et al., Nature 2015; Schwank et al., Cell Stem Cell 
2013). Finally, the in vitro stability of the organoid was 
demonstrated by the integration after transplantation of 
human liver cells into recipient mice. This makes the 
organoid a unique new platform for drug development, for 
precision medication for patients in the clinic, and a possible 
new source for cell therapy.  
 
SP-0099  
The role of ATM and p53 in normal tissue radiation 
response 
D. Kirsch
1Kirsch Lab, Durham, USA 
1 
 
Following ionizing radiation exposure, double strand DNA 
breaks activate the ataxia telangiectasia mutated (ATM) 
kinase, which then phosphorylates a large number of target 
proteins to orchestrate the DNA damage response. One of the 
key proteins that is activated by ionizing radiation in an ATM-
dependent manner is the tumor suppressor protein p53. Our 
laboratory has utilized the Cre-loxP system to delete ATM, 
p53 or both genes in different cell types in mice. We have 
also employed reversible in vivo shRNA to temporarily inhibit 
p53 during radiation exposure. We find that the roles of ATM 
and p53 in normal tissue radiation response are cell type 
specific. In bone marrow exposed to radiation, p53 acts to 
kill stem and progenitor hematopoietic cells, which increases 
acute hematological toxicity and promotes radiation-induced 
lymphomas. In gastrointestinal epithelial cells, p53 prevents 
the radiation-induced gastrointestinal syndrome. In 
endothelial cells, p53 prevents radiation-induced heart 
disease. Although deletion of ATM in endothelial cells does 
not sensitize mice to radiation-induced cardiac injury, in the 
setting of p53 deletion, ATM further sensitizes mice to 
radiation-induced heart disease. Taken together, these 
studies define cell type specific roles for ATM and p53 in 
mediating normal tissue response to ionizing radiation and 
suggest opportunities for combining radiotherapy with 
inhibitors of the ATM-p53 pathway to improve the 
therapeutic ratio when treating cancers at specific anatomic 
sites. 
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Due to its anatomical localization and high turnover, 
epidermis is a major target for carcinogens, and skin 
carcinoma is one of the most frequent human cancers. 
Ionizing radiation (IR) can induce carcinoma in skin, but the 
respective roles of keratinocyte stem cells and their progeny 
in the carcinogenic process is unclear. We characterized cell 
intrinsic radiosensitivity of keratinocyte stem cells (KSC) to 
gamma rays. Primary KSC were found radioresistant to high 
radiation doses (Rachidi, 2007), as well as to low doses. They 
repair rapidly all types of DNA damage (Harfouche, 2010), 
both after ionizing radiation and UVB exposure (Marie, 
submitted), without going to apoptosis. Activated repair was 
notably due to increased levels of DNA repair proteins and 
activation of nuclear FGF2 signaling. To evaluate the 
potential impact of irradiation on the epigenetic status of 
keratinocyte precursor cells, the Illumina 450K array was 
used, which measures the methylation level of 480,000 
methylation sites (or CpG islands). More than 36 million of 
GpCs have been identified in the human genome, most of 
them located directly in gene sequences or in gene 
promoters. In the present study, analysis of the lists of the 
modified genes obtained by normalized graph-cut DNA-
ranking allowed the definition of: 1) a specific signature of 
long-term alterations after 2 Gy: hundred genes presented 
methylation changes over 3 weeks in culture, with 18 genes 
exhibiting the most discriminant methylation changes at 16 
and 23 days after exposure. Six genes were members of the 
super-family of protocadherins of the alpha type, pointing to 
alterations of cell-cell interactions. 2) a specific signature of 
long-term alterations after 10 mGy: 15 specific genes had 
methylation changes that were discriminant after 16 and 23 
days. From their functions, it appears that the major cell 
responses after 10 mGy were localized at the cell membrane, 
for processes involved in calcium-related cell adhesion, 
signaling, energy status and carcinoma development. As a 
major function of methylation changes is to inhibit 
transcription, these signatures have been validated by 
characterizing the expression of the genes found in the 
signatures. In summary, high and low-dose exposures of 
immature keratinocytes from human epidermis result in 
epigenetic changes, part of them being specific to the dose. 
Methylation changes appear to regulate notably cell functions 
related to cell-cell interactions, cell adhesion and energy 
status.  
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Background: One of the main aims of radiotherapy alone or 
combined with chemo-, immuno- or biologically targeted 
therapy is the maximisation of tumour tissue eradication 
whilst preserving the surrounding normal tissue. This requires 
a deep understanding of the molecular mechanisms of 
radiation sensitivity in order to identify its key players and 
potential therapeutic targets. Currently, a paradigm shift is 
taking place from pure frequentistic association analysis to 
the rather holistic systems biology approach that seeks to 
mathematically model the system to be investigated and to 
allow the prediction of an altered phenotype as the function 
of one single or a signature of biomarkers.  
 
Methods: In the current study cell culture models of 
radiation-resistant tumour cells and normal radiation-
sensitive cells were investigated by multi-level (genome, 
transcriptome, miRNA) omics profiling over time and the 
resulting multi-layer radiation interactome was 
reconstructed. Validation of key network elements in biopsy-
derived multi-omics data from radiotherapy treated HNSCC 
patients was performed and tested for association with 
clinical outcome.  
 
Results: Molecular frameworks including signalling pathways 
senescence, cell cycle, immune system and PI3K/Akt have 
been identified and are therefore likely to drive radiation 
response in tumour and normal cells. Moreover, the 
identified networks could be used to identify molecular key 
players and potential targets for the simultaneous modulation 
